Huang Fang-Jun, He Yang, Tang Jun, Zhang Meng, Chen Jian, Mu De-Zhi
Department of Pediatrics, West China Second Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Nov 15;24(11):1183-1188. doi: 10.7499/j.issn.1008-8830.2205158.
International guidelines regarding the role of intravenous immunoglobulin (IVIG) in the management of Rh- and ABO-mediated haemolytic disease of the newborn was drafted by an international panel of experts in the fields of hematology, neonatology, and blood transfusion and was published in on March 16, 2022. The guidelines summarize the evidence-based practice of IVIG in Rh- and ABO-mediated haemolytic disease of the newborn and propose related recommendations. The guidelines recommend that IVIG should not be applied as a routine treatment regimen for Rh- and ABO-mediated haemolytic disease of the newborn in order to reduce exchange transfusion (ET), and the best time to apply IVIG remains unclear in the situations where hyperbilirubinaemia is severe (approaching or exceeding the ET threshold) or ET cannot be implemented. These guidelines are formulated with rigorous methods, but with the lower quality of evidence.
关于静脉注射免疫球蛋白（IVIG）在新生儿Rh和ABO血型介导的溶血病管理中作用的国际指南，由血液学、新生儿学和输血领域的国际专家小组起草，并于2022年3月16日发表。这些指南总结了IVIG在新生儿Rh和ABO血型介导的溶血病中的循证实践，并提出了相关建议。指南建议，为减少换血治疗（ET），IVIG不应作为新生儿Rh和ABO血型介导的溶血病的常规治疗方案，在高胆红素血症严重（接近或超过ET阈值）或无法实施ET的情况下，应用IVIG的最佳时机仍不明确。这些指南制定方法严谨，但证据质量较低。
